Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorhexidine gluconate + alcohol is an investigational mouthwash formulation containing 0.12% chlorhexidine gluconate and ethanol, specifically studied by researchers at the Federal University of Rio Grande do Sul (UFRGS) for the control of dental plaque (biofilm). Chlorhexidine is a cationic bisbiguanide that acts as a broad-spectrum antiseptic by binding to bacterial cell walls and membranes, causing membrane disruption and leakage of intracellular components. Alcohol in the formulation serves as a solvent and auxiliary antiseptic. In clinical trials (NCT02656251), this formulation was compared against an alcohol-free version and a placebo to evaluate its efficacy in inhibiting supra- and subgingival biofilm formation. While effective, the alcohol-containing version was noted to have lower patient acceptance compared to the alcohol-free alternative due to potential side effects like mucosal irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine gluconate + alcohol.